Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update Academic Article uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews. Substantive changes were made to the guideline recommendations including the inclusion of palonosetron to the 5-HT3 antagonists recommended for children receiving highly emetogenic chemotherapy (HEC) and the recommendation of aprepitant for children 6 months of age or older receiving HEC. To optimize CINV control in children, future work must focus on closing critical research gaps.

authors

  • Patel, Priya
  • Robinson, Paula D
  • Thackray, Jennifer
  • Flank, Jacqueline
  • Holdsworth, Mark T
  • Gibson, Paul
  • Orsey, Andrea
  • Portwine, Carol
  • Freedman, Jason
  • Madden, Jennifer R
  • Phillips, Robert
  • Sung, Lillian
  • Dupuis, L Lee

publication date

  • October 2017